Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

NCT ID: NCT01208129

Last Updated: 2013-07-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

458 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of this study are to assess the safety of NAB001 for topical treatment of mild to moderate distal onychomycosis of the toenails over 52 weeks and to compare the efficacy of NAB001 to vehicle alone at the end of the study (Week 56) after treating for 52 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Onychomycosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active drug

Group Type EXPERIMENTAL

NAB001

Intervention Type DRUG

nail lacquer, once daily, 52 weeks

Vehicle alone

Group Type PLACEBO_COMPARATOR

Placebo control

Intervention Type DRUG

nail lacquer, once daily, 52 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NAB001

nail lacquer, once daily, 52 weeks

Intervention Type DRUG

Placebo control

nail lacquer, once daily, 52 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* mild to moderate fungal infection of the toenail as assessed by study doctor
* koh positive \& dermatophyte culture positive at Visit 1
* general good health as assessed by study doctor

Exclusion Criteria

* severe fungal toenail infection
* prior use of antifungal drugs (wash-out allowed, duration varies on class)
* significant confounding conditions as assessed by study doctor
* pregnancy/lactation
* must forego nail salon procedures during study for at least \~60 weeks
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Promius Pharma, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kent Allenby, MD

Role: STUDY_DIRECTOR

Promius Pharma

Joanne Fraser, PhD

Role: STUDY_DIRECTOR

Promius Pharma

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Radiant Research, Inc.

Tucson, Arizona, United States

Site Status

Associated Foot & Ankle Specialists, LLC

Phoenix, Arkansas, United States

Site Status

Family Foot Health Center

Rogers, Arkansas, United States

Site Status

Center for Dermatology Clinical Research, Inc.

Fremont, California, United States

Site Status

UCSF Dermatology Research

San Francisco, California, United States

Site Status

Avail Clinical Research

DeLand, Florida, United States

Site Status

North Florida Dermatology Association

Jacksonville, Florida, United States

Site Status

Altus Research

Lake Worth, Florida, United States

Site Status

Lake Washington Foot and Ankle Center

Melbourne, Florida, United States

Site Status

Park Avenue Dermatology

Orange Park, Florida, United States

Site Status

Radiant Research, Inc.

Pinellas Park, Florida, United States

Site Status

Deaconess Clinic Downtown

Evansville, Indiana, United States

Site Status

Michigan Center for Skin Care Research

Clinton Township, Michigan, United States

Site Status

Department of Veteran's Affairs

Minneapolis, Minnesota, United States

Site Status

Pinkas Lebovits

New York, New York, United States

Site Status

Skin Search of Rochester, Inc.

Rochester, New York, United States

Site Status

Care Plus Podiatry, PC

Wading River, New York, United States

Site Status

Oregon Medical Research Center, PC

Portland, Oregon, United States

Site Status

Radiant Research, Inc.

Greer, South Carolina, United States

Site Status

The Skin Wellness Center, PC

Knoxville, Tennessee, United States

Site Status

Research Across America

Plano, Texas, United States

Site Status

Endeavor Clinical Trials

San Antonio, Texas, United States

Site Status

Dermatology Research Center

Salt Lake City, Utah, United States

Site Status

Coastal Podiatry, Inc.

Virginia Beach, Virginia, United States

Site Status

Madison Skin and Research, Inc.

Madison, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0903

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TDT 067 Onychomycosis Study
NCT01145807 UNKNOWN PHASE3